Skip to main content


Feuerstein's Biotech-Stock Mailbag

Vertex's cystic fibrosis compound shows promise, but be cautious in your enthusiasm. Also, an update on the quest for blood substitutes.

Feuerstein's Biotech-Stock Mailbag

Feuerstein backs his bearish stance on Cell Genesys' prostate cancer vaccine.

Feuerstein's Biotech-Stock Mailbag

Cell Genesys' 'news' this week doesn't do much to boost prospects for its prostate cancer vaccine.

Encysive Snags a Buyer

Pfizer agrees to buy the troubled blood pressure drug maker for $195 million.

Health Care's 10 Dumbest Things, Part Two

WellCare and Encysive were among this year's big losers.

Breaking News

Amazon Plans New 'Prime Early Access' Event in Race For Holiday Market Share

Prime Early Access will offer "deep discounts on top brands" and follow a move by Target to bring forward holiday-focused sales.

Las Vegas Sands Stock Leaps As Macau Eases Covid-Era Gaming Visit Restrictions

Macu, the world's largest gaming hub and a key source of U.S. casino operators revenues, will begin allowing tour visits in November.

Short Sellers Targeted Commodities in September

Short sellers reversed course and sold $19 billion of shorts in September.

Alphabet CEO Pichai Continues to Sound Alarm About the Economy

The parent company of Google and Youtube is preparing for a sharp deterioration in the health of the economy.